Trial · NCT00681889
Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
NCT00681889, Phase 1, Completed, Reza Dana, MD; results first posted 2012-11-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV). Trials, record NCT00681889. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00681889
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)
- NCT number
- NCT00681889
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 9 participants, actual
- Lead sponsor
- Reza Dana, MD
- Conditions
- Corneal Neovascularization
- Interventions
- Ranibizumab
- First posted
- 2008-05-21
- Last updated
- 2012-11-08
- Results first posted
- 2012-11-08
- Limitations and caveats
- Further and larger studies are needed to better establish the efficacy profile of this drug and optimize its dosing and formulation.
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and Severity of Ocular Adverse Event | 16 Weeks | Incidence and severity of ocular adverse events, as identified by eye examination and visual acuity testing |
| Primary | Incidence and Severity of Other Adverse Events, as Identified by Physical Examination, Subject Reporting, and Changes in Vital Signs | 16 Weeks | |
| Secondary | Efficacy by Comparison Size and Extent of Blood Vessels in Baseline and Follow-up Corneal Photographs | Prospective | |
| Secondary | Efficacy by Measuring Mean Change of BCVA | Prospective |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence and Severity of Ocular Adverse Event | 16 Weeks | All participants enrolled into the study were analyzed. | participants | NUMBER |
| PRIMARY | Incidence and Severity of Other Adverse Events, as Identified by Physical Examination, Subject Reporting, and Changes in Vital Signs | 16 Weeks | |||
| SECONDARY | Efficacy by Comparison Size and Extent of Blood Vessels in Baseline and Follow-up Corneal Photographs | Prospective | |||
| SECONDARY | Efficacy by Measuring Mean Change of BCVA | Prospective |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence and Severity of Ocular Adverse Event | Treatment Arm | 0 | participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment Arm | 9 | |
| Overall Study | COMPLETED | Treatment Arm | 9 | |
| Overall Study | NOT COMPLETED | Treatment Arm | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment Arm | ||
| Total, other adverse events | Treatment Arm | 0 | 9 |
| Total, serious adverse events | Treatment Arm | 0 | 9 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00681889
GET https://conductscience.org/api/trials/v1/NCT00681889/registered